# Verbund

Type: Company (OEZVY)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/verbund
Canonical HTML page: https://getbiobrief.com/entity/verbund

## Timeline

- **2026-03-18**: Quarterly Earnings — Expected announcement of financial results and pipeline updates for PTGX and OEZVY.
- **2025-Q4**: JNJ-2113 Phase 3 Progress — Johnson & Johnson advances oral peptide JNJ-2113 into pivotal trials.
- **2024-01-31**: Takeda Partnership — Protagonist signs a global licensing agreement for rusfertide with $300M upfront.

## Recent coverage (1 stories)

### Protagonist Therapeutics Braces for Q1 Earnings Amid Pipeline Milestones
2026-03-17 07:33:39 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Protagonist Therapeutics (PTGX) is set to report quarterly earnings this Wednesday, with investors focused on the commercial trajectory of its Takeda-partnered rusfertide. The results come at a critical juncture as the company transitions from a clinical-stage R&D house to a commercially-oriented biotech entity.
Full story: https://getbiobrief.com/story/protagonist-therapeutics-verbund-earnings-preview-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.